IVAX Receives Generic Drug Approval for Flutamide Capsules.Business Editors & Health/Medical Writers MIAMI--(BUSINESS WIRE)--Sept. 20, 2001 IVAX Corporation (AMEX AMEX See: American Stock Exchange :IVX)(LSE LSE - Language Sensitive Editor :IVX.L) received approval for its Abbreviated New Drug Application abbreviated new drug application Pharmacology An application made in the US by a pharmaceutical company requesting authority to market a 'new' drug for which both its therapeutic indications and formulation were previously approved by the FDA in another similar (ANDA) for sales of flutamide capsules in 125 mg strength from the United States Food and Drug Administration United States Food and Drug Administration (FDA), n.pr a unit of the Public Health Service created to protect the health of the nation against impure and unsafe foods, drugs, and cosmetics. (FDA FDA abbr. Food and Drug Administration FDA, n.pr See Food and Drug Administration. FDA, n.pr the abbreviation for the Food and Drug Administration. ). Flutamide is used to treat prostate cancer and is the generic equivalent of Schering Corporation's Eulexin(R) Capsules. IVAX will immediately sell this product through its wholly owned subsidiary Wholly Owned Subsidiary A subsidiary whose parent company owns 100% of its common stock. Notes: In other words, the parent company owns the company outright and there are no minority owners. , IVAX Pharmaceuticals, Inc. Sales of Eulexin Capsules were approximately $48 million in 2000. This marks IVAX' seventh generic drug approval so far this year - with 32 ANDAs and tentative approvals currently pending at the FDA. The company is continuing its aggressive filing schedule for new ANDA submissions. IVAX Corporation, headquartered in Miami, Florida, is engaged in the research, development, manufacturing, and marketing of branded and brand equivalent pharmaceuticals and veterinary and diagnostic products in the U.S. and international markets. Except for the historical matters contained herein, statements in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act The Private Securities Litigation Reform Act of 1995 (PSLRA) implemented several significant substantive changes affecting certain cases brought under the federal securities laws, including changes related to pleading, discovery, liability, class representation and awards fees and of 1995. Investors are cautioned that forward-looking statements, including the statements regarding IVAX' pending ANDAs and tentative approvals and filing schedule for ANDA submissions, involve risks and uncertainties which may affect the company's business and prospects, including the risks that IVAX Pharmaceuticals may not launch flutamide capsules in 125 mg strength or that its launch will be delayed; that IVAX may not receive approval of its pending ANDAs or final approval of its tentatively approved ANDAs, or that if approved, the products will not be successfully commercialized; that IVAX may not file any additional ANDAs; and other risks and uncertainties based on economic, competitive, governmental, technological and other factors discussed in the Company's 2000 Annual Report on Form 10-K and its other filings with the Securities and Exchange Commission. Eulexin(R) Capsules is a registered trademark of Schering Corporation. |
|
||||||||||||||
Printer friendly
Cite/link
Email
Feedback
Reader Opinion